Skip to content

Assessing the significance of CCNE1 overexpression in triple negative breast cancer.

Jul 2026 · Clinical and Translational Oncology · 0 citations · 35 references
Medicine

TL;DR

CCNE1 overexpression characterises a clinically aggressive subset of breast cancers, particularly TNBC, and targeting mTORC1 may represent a promising therapeutic approach in CCNE1-high, TP53-mutated, and RB1-deficient tumours, supporting the clinical utility of CCNE1 in patient stratification and targeted therapy.

View source

Similar papers

Aug 2026

CDC20B Dysregulation: Links to Tumor Prognosis and Immunity.

CDC20B may contribute to tumor progression in a context-dependent manner, with its prognostic impact varying across cancer types, and promoter hypomethylation emerges as a potential epigenetic driver of overexpression.

Hong-Rong Wu, Liang-Li Hong · 0 citations
Open access Aug 2026

Prognostic value of FUBP1 in Colorectal cancer and association with immune microenvironment characteristics.

OBJECTIVE To investigate FUBP1 expression, its prognostic value, impact on the tumor microenvironment (TME), and drug sensitivity in colorectal cancer (CRC), and to explore its potential underlying mechanisms. METHODS Using data from The Cancer Genome Atlas (TCGA), we analyzed FUBP1 expression in CRC, evaluated its p...

Zhen-Xiang Li, Yan-Fang Zhao, Yan-Li Si et al. · 0 citations
Sep 2026

NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.

NOC4L shows promise as a dual-action target, functioning both as a prognostic biomarker and as a potential immunotherapeutic target, and is associated with overall survival in 20 cancer types, suggesting its potential as an independent prognostic marker.

Hai Bai, Wan-Qing Xu, Guo-Zheng Wei et al. · 0 citations
Open access Aug 2026

GNG12 overexpression inhibits triple-negative breast cancer cell proliferation, migration, and invasion

GNG12 was found to be broadly downregulated in TNBC and associated with suppression of malignant cellular phenotypes; however, its clinical significance and mechanistic relationship with PI3K/AKT signaling require further validation in larger cohorts and additional experimental models.

Biao-Feng Shan, Le Zhao, Tao Hu et al. · 0 citations
Open access Aug 2026

TPD52 promotes breast cancer cell migration, invasion and proliferation via activation of the MAPK/ERK signaling pathway

Elevated TPD52 expression was associated with longer overall survival in specific subgroups, including the basal-like subtype, invasive lobular carcinoma, and N0/N1 stages, and a random forest-based diagnostic model demonstrated high accuracy across multiple datasets.

J. Yu, Z. Zhu, R. Deng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.